ArticleFrontiers in immunology2026
Immune reconstitution and infections with ATG versus post-transplant cyclophosphamide as GvHD prophylaxis after nonmyeloablative matched unrelated donor hematopoietic stem cell transplantation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PTCy) are both used as Methods: In this retrospective study, we compared the incidences of infections and viral reactivations and evaluated immune cell reconstitution in the first-year post-transplant between ATG- and PTCy-based conditioning regimens in nonmyeloablative MUD transplantations. Infection incidence was evaluated for the periods 0-100 vs. 101-365 days post-transplant. Results: A total of 185 patients (ATG=95, PTCy=90), transplanted between 2014 and 2021, were included. In the first 100 days after transplantation, the cumulative incidence of bacterial infections was higher in the PTCy group (ATG 17% vs. PTCy 32%, p=0.01) while CMV reactivations were more frequent in the ATG group (36% vs. 16%, p<0.001). Beyond 100-days post-transplant, incidence of bacterial infections was higher in the ATG group (18% vs. 1%, p<0.001). Fungal infection incidence was similar in both groups/periods. The 1-year densities of viral infections (3.54 vs. 1.89, p<0.01) and CMV reactivations (2.21 vs. 0.68, p<0.01) were higher in the ATG compared to the PTCy group. After 1-year, circulating CD4+ T-cell counts were significantly lower in the ATG than in the PTCy group (p<0.001). Discussion: In conclusion, this study shows that overall PTCy is associated with better immune reconstitution and reduced rate of viral infections/CMV reactivations compared to ATG-based conditioning. Together with our previous findings of a lower risk of acute GvHD following PTCy compared to ATG-based conditioning, these data may favor PTCy over ATG as GvHD prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.